Skip to main content
letter
. 2021 Sep 23;93:105–106. doi: 10.1016/j.ejim.2021.09.009

Fig. 1.

Fig 1

The association of COVID-19 severity scores with sarcopenia status (A) and HGS (B), and the plasma CAF22 levels (C) of the participants in the absence or presence of sarcopenia at baseline, or development of sarcopenia during the disease course of COVID-19 infection (n = 117). One-way analysis of variance (A and C), **p < 0.01, ****p < 0.0001.